Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20528274 | 1.00 | TP53 (0.39) | TP53ALOX15ALDH1A1CA12CA1 | |
| Hydrochloric Acid SCHEMBL2212116 | 0.98 | TP53 (0.38) | TP53ALOX15ALDH1A1CA12CA1 | |
| Hydrochloric Acid SCHEMBL2212113 | 0.98 | TP53 (0.38) | TP53ALOX15ALDH1A1CA12CA1 | |
| SCHEMBL6433997 | 0.84 | TP53 (0.37) | TP53ALDH1A1CA1CA2LMNA | |
| SCHEMBL27594511 | 0.82 | ALOX15 (0.38) | TP53ALOX15ALDH1A1CA12CA1 | |
| SCHEMBL20528273 | 0.82 | TP53 (0.38) | TP53ALOX15ALDH1A1CA12CA1 | |
| SCHEMBL27594510 | 0.82 | ALOX15 (0.38) | TP53ALOX15ALDH1A1CA12CA1 | |
| SCHEMBL3766175 | 0.81 | CA14 (0.39) | TP53ALDH1A1CA12CA1CA2 | |
| SCHEMBL1786590 | 0.81 | CA14 (0.39) | TP53ALDH1A1CA12CA1CA2 | |
| SCHEMBL1786589 | 0.81 | CA14 (0.39) | TP53ALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| WO-2025199636-A1 | TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2025-10-02 | — | — | WO | claimed |
| EP-4619411-A1 | DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-09-24 | — | — | EP | claimed |
| WO-2024245421-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-12-05 | — | — | WO | claimed |
| WO-2024245407-A1 | CONJUGATES AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-12-05 | — | — | WO | claimed |
| US-20240350644-A1 | STEREOCOMPLEXES FOR THE DELIVERY OF ANTI-CANCER AGENTS | TIEN DER YANG (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024083224-A1 | DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF RELATED APPLICATIONS | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-04-25 | — | — | WO | claimed |
| US-20230201386-A1 | PRODUCING RADIOPHARMACEUTICAL COLD KITS WITHOUT LYOPHILIZATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2023-06-29 | — | — | US | claimed |
| EP-4137527-A1 | STEREOCOMPLEXES FOR THE DELIVERY OF ANTI-CANCER AGENTS | TIEN, Der-Yang (US) | 2023-02-22 | — | — | EP | claimed |
| US-20040228781-A1 | chemical reactors having microstructure passageways, catalysts supports, absorber materials and heat exchangers | VELOCYS, INC. | 2004-11-18 | — | — | US | claimed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | claimed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2004041414-A1 | PROCESS FOR SEPARATING A FLUID COMPONENT FROM A FLUID MIXTURE BY SORPTION USING MICROCHANNEL PROCESS TECHNOLOGY | VELOCYS, INC. (US) | 2004-05-21 | — | — | WO | claimed |
| US-6652627-B1 | Process for separating a fluid component from a fluid mixture using microchannel process technology | VELOCYS, INC. | 2003-11-25 | — | — | US | claimed |
| US-5843420-A | Method for extracting malodorous compounds present in a formulation containing at least one compound carrying a thiol group and deodorized compositions thus obtained | L'OREAL (FR) | 1998-12-01 | — | — | US | claimed |
| EP-0626166-B1 | New process for permanent waving of hair and the composition therefor containing in association an amino or amidothiol and at least a mineral bromide | OREAL (FR) | 1997-03-19 | — | — | EP | claimed |
| US-5531987-A | Method for extracting malodorous compounds present in a formulation containing at least one compound carrying a thiol group and deodorized compositions thus obtained | L'OREAL (FR) | 1996-07-02 | — | — | US | claimed |
| US-5458848-A | Deodorizing | L'OREAL (FR) | 1995-10-17 | — | — | US | claimed |
| US-5262175-A | Containing technetium by addition of an oxidizing agent | SOLANKI KISHOR K (GB) | 1993-11-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350644-A1 | STEREOCOMPLEXES FOR THE DELIVERY OF ANTI-CANCER AGENTS | TOP2A, TSG101, TOP1 | TP53 7/4885ALOX15 4154/4885ALDH1A1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.